placeCanada – English
Contact Us
Medtronic / Products / Brain Monitoring / BIS™ TIVA

BIS™ technology for TIVA

Monitoring with BIS™ technology empowers you with an accurate, direct measurement of the propofol effect on your patient’s brain.

  • Allows clinicians to personalize dosing for each patient
  • Administering just the right dose to reduce complications from too much (burst suppression) or too little (awareness)
     

Make a difference in post anesthesia outcomes

In order to personalize your propofol dosing based on the individual needs of each patient, you need a direct measurement of the propofol effect on your patient’s brain. BIS™ monitoring empowers you by accurately reflecting the anesthetic effect on your patient’s brain, allowing you to personalize dosing to:

  • Use less anesthetic agents1,5-8
  • Improve emergence and recovery times1–4
  • Reduce postoperative delirium up to 29%1,2,9
     

Contact us

Reduce use of anesthetic agents

  • Use up to 38% less anesthetic agents1,5-8
  • BIS™ monitoring enabled a 50% reduction in propofol administration during one study of hypothermic cardiopulmonary bypass10

Improved Emergence, Recovery, and Discharge

  • Patients monitored with BIS™ technology wake up 27–53% faster in the OR7
  • 87% increase in “excellent/fully oriented” status on PACU admission7
  • Faster discharge from the PACU helps minimize OR delays11
  • Reduce confirmed awareness with explicit recall (AWR) by 78%2

Clinical Evidence

Improving anesthetic delivery and postoperative recovery

“Bispectral index (BIS)-guided anaesthesia may also reduce early recovery parameters of the time to eye opening, the time to orientation, and the time to discharge from the postanaesthesia care unit (PACU).”1

– Authors Sharon Lewis, et al., in a clinical review of bispectral index for improving anesthetic deliver and postoperative recovery in adults.

Nice guidelines recommend BIS™ monitoring

“BIS™ monitoring is recommended as an option for all patients receiving total intravenous anesthetic (TIVA). BIS™ technology is also cost effective in this patient population due to the inability to measure end-tidal anesthetic concentration.”12

– National Institute for Health and Clinical Excellence

Intraoperative awareness prevention

“…in intravenous anesthesia, BIS™ monitoring could reduce the incidence of intraoperative awareness by approximately 80% (0.1448% versus 0.7330%).”9

– Author Wen-Wei Gao, et al., in a clinical review on BIS™ monitoring on interoperative awareness

Educational Opportunities

Access training portal

Brain monitoring training pathways

Listen to MedEd podcast

Interview-style discussions on anesthesia and the brain

Check MedEd Bytes

A “byte”-sized educational video series

Watch webinars

A library of brain monitoring webinars

Related Products

BIS™ Advance Monitor

BIS™ Advance Monitor
BIS™ 4-Channel Monitor

BIS™ 4-Channel Monitor
BIS™ Quatro Sensor

BIS™ Quatro Sensor
BIS™ Bilateral Sensor

BIS™ Bilateral Sensor

BIS™ Brain Monitoring System *

Learn more about BIS™ monitors and sensors.

View Brochure

HCP Resources

Explore additional resources, best practices, and insights for healthcare professionals.

View Resources

  • The BIS™ monitoring system should not be used as the sole basis for diagnosis or therapy and is intended only as an adjunct in patient assessment. Reliance on the BIS™ monitoring system alone for intraoperative anesthetic management is not recommended.

     

  • 1. Lewis SR, Pritchard MW, Fawcett LJ, Punjasawadwong Y. Bispectral index for improving intraoperative awareness and early postoperative recovery in adults. Cochrane Database Syst Rev. 2019;9:CD003843. doi:10.1002/14651858.CD003843.pub4.

  • 2. Zhang C, Xu L, Ma Y-Q, et al. Bispectral index monitoring prevent awareness during total intravenous anesthesia: a prospective, randomized, double-blinded, multi-center controlled trial. Chin Med J (Engl). 2011;124(22):3664-3669

  • 3. Myles PS, Leslie K, McNeil J, Forbes A, Chan MTV. Bispectral index monitoring to prevent awareness during anaesthesia: The B-Aware randomised controlled trial. Lancet. 2004;363(9423):1757-1763. doi:10.1016/S0140-6736(04)16300-9.

  • 4. Ekman A, Lindholm M-L, Lennmarken C, Sandin R. Reduction in the incidence of awareness using BIS monitoring. Acta Anaesthesiol Scand. 2004;48(1):20-26. doi:10.1111/j.1399-6576.2004.00260.x.

  • 5. Punjasawadwong Y, Phongchiewboon A, Bunchungmongkol N. Bispectral index for improving anaesthetic delivery and postoperative recovery. Cochrane Database Syst Rev. 2014;(6):CD003843. doi:10.1002/14651858.CD003843.pub3.

  • 6. Song D, Joshi GP, White PF. Titration of volatile anesthetics using bispectral index facilitates recovery after ambulatory anesthesia. Anesthesiology. 1997;87(4):842-848.

  • 7. Gan TJ, Glass PS, Windsor A, et al. Bispectral index monitoring allows faster emergence and improved recovery from propofol, alfentanil and nitrous oxide anesthesia. Anesthesiology. 1997;87(4):808-815. doi:10.1097/00000542-199710000-00014

  • 8. Luginbuhl M, Wuthrich S, Petersen-Felix S, Zbinden AM, Schnider TW. Different benefit of bispectal index (BIS) in desflurane and propofol anesthesia. Acta Anaesthesiol Scand. 2003;47(2):165-173. 

  • 9. Gao WW, He YH, Liu L, Yuan Q, Wang YF, Zhao B. BIS monitoring on intraoperative awareness: a meta-analysis. Current medical science. 2018;38(2):349-53.

  • 10. Chiu CL, Ong G, Majid AA. Impact of bispectral index monitoring on propofol administration in patients undergoing cardiopulmonary bypass. Anaesthesia Intensive Care. 2007;35:342-347.

  • 11. Lau CSM, Chamberlain RS. Enhanced recovery after surgery programs improve patient outcomes and recovery: A meta-analysis. World J Surg. 2017;41: 899–913. doi: 10.1007/s00268-016-3807-4.

  • 12. National Institute for Health and Clinical Excellence. Depth of anaesthesia monitors (E-Entropy, BIS™ and Narcotrend) (DG6). November 2012. 

  • * Licenced as EEG COMPLETE MONITORING SYSTEM

Corporate Resources
Minimally Invasive Therapies
Contact Us
Medtronic Canada Headquarters

99 Hereford Street

Brampton, Ontario

L6Y 0R3

Canada

©2024 Medtronic
US-PM-2300367: 2023-09